Evidence map›Paper›PMID 32300922›Full record

Observational studyBreast cancer research and treatment2020

Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.

Charlotte Levin Tykjær Jørgensen, Carina Forsare, Pär-Ola Bendahl, Anna-Karin Falck, Mårten Fernö, Kristina Lövgren, Kristina Aaltonen, Lisa Rydén

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Unleashing Wnts: Wnt Ligands Fuel Cancer Spread.Journal of cancer biology · 2025
    Article
  12. Review
  13. Contribution of PKS+Heliyon · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Charlotte Levin Tykjær JørgensenDivision of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University, Medicon Village, Building 404, 22381, Lund, Sweden. charlotte.levin_tykjaer_jorgensen@med.lu.se.
Carina ForsareDivision of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University, Medicon Village, Building 404, 22381, Lund, Sweden.
Pär-Ola BendahlDivision of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University, Medicon Village, Building 404, 22381, Lund, Sweden.
Anna-Karin FalckDepartment of Surgery, Helsingborg Hospital, Helsingborg, Sweden.
Mårten FernöDivision of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University, Medicon Village, Building 404, 22381, Lund, Sweden.
Kristina LövgrenDivision of Oncology and Pathology, Department of Clinical Sciences, Lund, Lund University, Medicon Village, Building 404, 22381, Lund, Sweden.
Kristina AaltonenDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Lisa RydénDivision of Surgery, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.
Lund University · SEHelsingborgs lasarett · SEMedicon Village · SESkåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe study aimed to investigate expression of epithelial-to-mesenchymal transition (EMT)-related proteins and phenotypes during breast cancer progression and to relate this to patient outcome.

methodsProtein expression patterns of E-cadherin, N-cadherin, twist, and vimentin were examined by immunohistochemistry on formalin-fixed paraffin-embedded samples from primary tumors (PTs) (n = 419), synchronous lymph node metastases (LNMs) (n = 131) and recurrences (n = 34) from patients included in an observational prospective primary breast cancer study. Markers were evaluated individually and combined as defined EMT phenotypes (epithelial, mesenchymal, partial EMT, and negative). EMT profiles were compared between matched tumor progression stages, and related to clinicopathological data and distant recurrence-free interval (DRFi).

resultsN-cadherin-positivity, vimentin-positivity, mesenchymal and partial EMT phenotypes were associated with more aggressive tumor characteristics such as triple-negative subtype. Single EMT markers and phenotype discordance rates between paired tumor samples were observed in the range of 2-35%. Non-epithelial phenotypes were more frequently identified in recurrences compared to PTs, however, no skewness of expression or phenotype was detected between PTs and matched LNMs or between PTs and matched recurrences (Exact McNemar test). Interestingly, patients with a twist positive PT had shorter DRFi, compared to patients with a twist negative PT (hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.2-5.1, P = 0.02). Essentially, the same effect was seen in multivariable analysis (HR 2.5, 95% CI 0.97-6.6, P = 0.06).

conclusionThe epithelial phenotype was indicated to be lost between PTs and recurrences as a reflection of tumor progression. Twist status of the PT was related to long-term prognosis warranting further investigation in larger cohorts.

Indexed as

Epithelial-Mesenchymal TransitionPhenotypeAntigens, CDBiomarkers, TumorBreast NeoplasmsCadherinsDisease ProgressionErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisProspective StudiesReceptors, EstrogenAntigens, CDBiomarkers, TumorCadherinsCDH1 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneVimentinBreast cancerEMT phenotypesEpithelial-mesenchymal transitionPrimary tumorRecurrenceTumor progression

Identifiers

PMID32300922
PMCPMC7188722
OpenAlexW3016390081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.